FDA Grants RMAT Designation to Allogeneic CAR T for R/R Multiple Myeloma

The U.S. Food and Drug Administration has granted regenerative medicine advanced therapy (RMAT) designation to CB-011, an allogeneic anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy being developed for patients with relapsed or refractory multiple myeloma (R/R MM). The designation is expected to accelerate clinical development and regulatory review, building on the therapy’s earlier fast track and orphan drug status. The decision reflects growing momentum in the BCMA-targeted therapies space, particularly for patients with limited treatment options.

The RMAT designation was supported by early clinical data from the ongoing Camouflage phase 1 trial, which evaluates CB-011 in heavily pretreated patients. In a cohort of 12 anti-BCMA–naive patients treated at the recommended expansion dose, the therapy demonstrated a 92% overall response rate, with 75% achieving complete response or better. Additionally, 91% of evaluable patients achieved minimal residual disease negativity, highlighting a strong efficacy signal in a population with significant unmet medical need.

Across the broader study population of 48 patients, CB-011 exhibited a manageable safety profile. No cases of graft-versus-host disease, immune effector cell–associated enterocolitis, Parkinsonism, or cranial nerve complications were reported. The therapy’s off-the-shelf allogeneic design, enabled through advanced CRISPR-based gene editing, is intended to overcome access limitations associated with autologous CAR T approaches, potentially improving scalability and patient availability.

The ongoing trial continues to enrol patients with at least three prior lines of therapy, with expansion cohorts assessing efficacy in both BCMA-naive and previously exposed populations. Additional clinical data are anticipated in 2026, which could further strengthen the therapy’s regulatory pathway and commercial potential.

According to Precedence Research, the B-cell maturation antigen (BCMA) targeted therapies market size accounted for USD 5.60 billion in 2025 and is predicted to increase from USD 6.62 billion in 2026 to approximately USD 29.81 billion by 2035, expanding at a CAGR of 18.20% from 2026 to 2035 as demand rises for advanced immunotherapies targeting refractory hematologic malignancies.

A recent report by Precedence Research highlights that the B-cell maturation antigen (BCMA) targeted therapies market is benefiting from strong clinical advancements in CAR T-cell therapies, increasing regulatory support, and growing investment in next-generation gene-editing technologies aimed at improving treatment accessibility and patient outcomes.